News & Updates
Excerpt from the Article: AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) has announced Wednesday that the active AMP-511 Expanded Access Program (EAP) has dosed its first coronavirus (COVID-19) “Long Hauler” patient with the drug Ampligen (rintatolimod). The company said the initial dosing marks a significant milestone in its efforts to develop an effective therapeutic for people suffering…
Read More
Excerpt from the Article: In 1995, Katalin Karikó was at her lowest ebb. A biochemist at the University of Pennsylvania (UPenn), Karikó had dedicated much of the previous two decades to finding a way to turn one of the most fundamental building blocks of life, mRNA, into a whole new category of therapeutics. More often…
Read More
Excerpt from the Article: COVID-19 is known to cause neurological complications in patients who test positive for the virus, but new research from the National Institutes of Health (NIH) has revealed that SARS-CoV-2 does not always find its way into the brains of infected patients. Based on findings from high-powered MRI scans, researches from the…
Read More
Excerpt from the Press Release: Researchers at Children’s Hospital of Philadelphia (CHOP) have formed a new consortium that will study the effects of the COVID-19 pandemic on preterm birth and prenatal care, funded by $300,000 in grants from the Independence Blue Cross Foundation, Highmark Blue Cross Blue Shield Delaware’s donor-advised fund, and BluePrints for the…
Read More
Excerpt from the Article: A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat Covid-19. Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China, and colleagues present these findings in the open-access journal PLOS Computational…
Read More
Excerpt from the Article: Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Center. The boost helps recruit more…
Read More
Excerpt from the Press Release: UCLH has opened a new vaccine research centre with two clinical trials testing a long-acting antibody combination treatment to protect against Covid-19. Researchers in the STORM CHASER study led by UCLH virologist Dr Catherine Houlihan have recruited the first participant in the world to the study. They believe the antibody…
Read More
Excerpt from the Press Release: Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination – of irinotecan, cetuximab, and vemurafenib – is a more powerful tumor fighter and keeps people with metastatic…
Read More
Excerpt from the Article: A landmark paper published today in the New England Journal of Medicine describes the results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement in survival in patients with acute myeloid leukemia (AML). The Phase 3 clinical trial called QUAZAR, showed that a drug,…
Read More
Excerpt from the Article: Like most companies in 2020, Dexcom (NSDQ:DXCM) faced a number of challenges brought on by COVID-19, public unrest and more. Dexcom chairman, president & CEO Kevin Sayer had to prioritize the health of his employees over all else, while also keeping patients safe and somehow managing to keep the diabetes giant rolling…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?